---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006520"
form_type: "8-K"
ticker: null
cik: "0001851194"
company_name: "Ventyx Biosciences, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:24:45.493410+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Eli Lilly to acquire Ventyx Biosciences for $14.00 per share (~$1.2B equity value)

## Summary
- All-cash deal at $14.00/share; aggregate equity value of ~$1.2 billion.
- Premium of ~62% to 30-day volume-weighted average price as of Jan 5, 2026.
- Closing expected first half of 2026; subject to stockholder approval and regulatory clearance.
- Directors, officers, and New Science Ventures (10% of shares) signed voting agreements to support.
- Ventyx pipeline includes oral NLRP3 inhibitors for cardiometabolic, neurodegenerative, and autoimmune diseases.

## SEC filing metadata
- accession: 0001193125-26-006520
- form_type: 8-K
- cik: 0001851194
- company_name: Ventyx Biosciences, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851194/000119312526006520/0001193125-26-006520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851194/000119312526006520/d98679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006520
- JSON: https://secwatch.observer/filing/0001193125-26-006520.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006520.txt

## Key facts
- Material Agreements
  Ventyx Biosciences, Inc. entered into Merger Agreement with Eli Lilly and Company and its wholly owned subsidiary, RYLS Merger Corporation (effective 2026-01-07).
  - Action: entry
  - Agreement: merger
  - Counterparty: Eli Lilly and Company and its wholly owned subsidiary, RYLS Merger Corporation
  - Effective: 2026-01-07
  source text: On January 7, 2026, Ventyx Biosciences, Inc. (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Eli Lilly and Company, an Indiana corporation (“Parent”), and Parent’s wholly owned subsidiary, RYLS Merger Corporation, a Delaware corporation (“Merger Sub”), pursuant to which, subject to satisfaction or waiver of the conditions therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312526006520/0001193125-26-006520-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.